Aktuelles & Neues von uns und unseren Kunden

Ym Biosciences Announces Secondary Efficacy and Safety Findings in Randomized Phase Iib Aerolef(TM) Trial

Wednesday July 11, 7:00 am ET

- Company Announces Lead Investigator for U.S. Trial -

YM BioSciences announces preclinical data confirming nimotuzumab binds to the EGF receptor and potentiates radiotherapy

Monday July 9, 12:30 am ET

YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEF(TM)

Wednesday June 27, 7:00 am ET

- YM to initiate trial in the U.S. and plans End of Phase II meeting with FDA -

Feuerstein's Biotech-Stock Mailbag

By Adam Feuerstein

Senior Writer

6/9/2007 10:04 AM EDT

YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Children with inoperable recurrent Brain Cancer

Thursday June 7, 5:13 pm ET